You are here

Technology

Regenerative Medicine and COVID-19

A Perspective article evaluates some of the promising regenerative medicine‐based therapies for treating COVID‐19 and presents some of the collective technologies and resources available

Retinal Coculture Techniques

A new review discusses retinal coculture models of the neural retina, retinal pigment epithelium, and choriocapillaris

Emerging Cell‐based Therapies for SCI – A Review

A fascinating article succinctly provides readers with a working knowledge of SCI and cell therapies at the leading edge of research.

CIRM Tools and Technologies

The potential of human stem cells to alleviate disease was clear upon the inception of the California Institute for Regenerative Medicine's (CIRM). 

Strategies for Immune Tolerance and Immune Evasion

The California Institute for Regenerative Medicine has funded multiple programs in different disease areas and at various stages of therapeutic development

Epitranscriptome Landscape of sncRNAs in Stem Cells

Researchers led by Abdulrahim Sajini brings us up to date regarding how the epitranscriptome will play critical roles in regenerative medicine and RNA‐based therapeutics in the near future

Neurotrophic Effects of Decellularized Muscles

Skeletal muscle decellularization allows the generation of natural scaffolds that retain the extracellular matrix mechanical integrity, biological activity, and three‐dimensional (3D) architecture of the native tissue.

Efficacy Outcomes in Uncontrolled Trials

Interpretation of observed change in a continuous outcome measure as preliminary evidence of efficacy in the setting of an uncontrolled trial can lead to erroneous conclusions due to the effect of regression to the mean.

Stem Cell-derived Retinal Organoids: A Review

Retinal diseases that can lead to vision impairment or blindness currently suffer from a lack of effective treatment options.

Killers at The Crossroads

Adoptive cell therapy (ACT) as an approach to cancer treatment involves the administration of antitumor immune cells to target residual disease in patients after completion of chemo/radiotherapy. Currently, the identification and generation of antitumor effector cells that efficiently recognize tumor cells remain important barriers to the success of ACT in cancer clinical trials.

Pages

Subscribe to RSS - Technology